Please login to the form below

Not currently logged in
Email:
Password:

Tremfya heads for filing in psoriatic arthritis

Lilly's Talz sets pace with Humira head-to-head

tremfya

J&J’s Tremfya has hit its primary endpoints in two phase 3 studies in psoriatic arthritis (PsA) putting it on course for a filing with regulators later this year.

Tremfiya (guselkumab) is the follow-up to J&J’s IL-23/IL-12 inhibitor blockbuster Stelara, which is under assault from rival new entrants across immunology indications, most notably Novartis’ Cosentyx.

While Stelara remains in a solid second place behind runaway leader Humira, Cosentyx, AbbVie’s Skyrizi, Eli Lilly’s Taltz and Pfizer's Xeljanz also already approved in psoriatic arthritis.

J&J has unveiled top line data from the DISCOVER-1 and DISCOVER-2 phase 3 trials of Tremfya in patients with active PsA compared to placebo.

The drug hit its primary endpoint of ACR20 response at week 24, multiple secondary endpoints were assessed that included ACR50/70, resolution of soft tissue inflammation (enthesitis and dactylitis), disease activity (DAS-28 CRP), improvement in physical function (HAQ-DI), skin clearance (IGA), and quality of life (SF-36 PCS and MCS).
DISCOVER-2 also assessed effect on structural damage (vdH-S) as a key secondary endpoint.

DISCOVER-1 included 381 participants, including participants previously treated with anti-TNF biologics. The study continued through 52 weeks. DISCOVER-2 included 739 biologic-naive participants, and continued up to 100 weeks.
The study results were announced on Friday at the EULAR conference, and followed strong data from rivals.

This includes Novartis’ FUTURE 5 trial of Cosentyx in PsA, in which the company  demonstrated that Cosentyx can prevent the long term damage to joints which can ultimately disable patients. The FUTURE 5 study showed patients taking Cosentyx showed no radiographic progression in almost 90% of PsA patients over two years. Of the patients receiving the drug at 150 mg, 66.3% had rapid and significant improvements in symptoms of the disease with axial manifestations at week 12.

Probably the most eyecatching results in PsA from EULAR in Madrid, however, was Lilly's Talz in a head-to-head trial where it beat Humira.

Taltz showed itself superior to Humira in reducing PsA disease activity by half and also completely cleared patient skin after 24 weeks. Lilly's drug did show an inferior side-effect profile compared to Humira, however, with a higher rate of infections and injection-site reactions.

Article by
Andrew McConaghie

17th June 2019

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...
Clinical trial recruitment on podcasts: is it a good idea?
The pharmaceutical industry is already using social media and search engine advertising for clinical trials, so why not consider podcast platforms too?...
Healthcare in a lockdown
Even if patients are getting enough care during the COVID-19 pandemic, are they getting the right care?...

Infographics